TRHC - Tabula Rasa HealthCare Inc Stock Price, Fair Value and News

10.50USD Delayed

Market Summary

USD10.50

Delayed

TRHC Stock Price

View Fullscreen

TRHC RSI Chart

TRHC Valuation

Market Cap

284.1M

Price/Earnings (Trailing)

-2.98

Price/Sales (Trailing)

0.84

EV/EBITDA

-7.19

Price/Free Cashflow

-34.42

TRHC Price/Sales (Trailing)

TRHC Profitability

Operating Margin

23.61%

EBT Margin

-17.99%

Return on Equity

-26.55%

Return on Assets

-26.82%

Free Cashflow Yield

-2.91%

TRHC Fundamentals

TRHC Revenue

Revenue (TTM)

338.1M

TRHC Earnings

Earnings (TTM)

-95.5M

Breaking Down TRHC Revenue

Last 7 days

0.9%

Last 30 days

1.8%

Last 90 days

34.1%

Trailing 12 Months

167.9%

How does TRHC drawdown profile look like?

TRHC Financial Health

Current Ratio

1.57

Debt/Equity

0.25

Debt/Cashflow

-0.06

TRHC Investor Care

Shares Dilution (1Y)

3.06%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	320.7M	338.1M	0	0
2022	268.2M	276.5M	285.7M	299.5M
2021	207.3M	194.8M	192.2M	259.9M
2020	296.6M	297.2M	293.4M	221.4M
2019	221.3M	248.9M	268.8M	284.7M
2018	149.5M	168.6M	190.3M	204.3M
2017	101.9M	108.9M	117.5M	133.5M
2016	74.7M	80.3M	86.5M	94.1M
2015	53.8M	59.2M	64.6M	70.0M
2014	0	0	0	48.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tabula Rasa HealthCare Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 03, 2023	schwartz jonathan david	back to issuer	-	-	-78,388	-
Nov 03, 2023	indaba capital management, l.p.	back to issuer	-69,299,600	10.5	-6,599,970	-
Nov 03, 2023	adams brian w	back to issuer	-	-	-767,311	chief executive officer
Nov 03, 2023	helling dennis	back to issuer	-	-	-112,109	-
Nov 03, 2023	cancro thomas	back to issuer	-	-	-304,092	chief financial officer
Nov 03, 2023	schweitzer pamela	back to issuer	-	-	-9,784	-
Nov 03, 2023	bruno michael anthony	back to issuer	-	-	-22,955	chief accounting officer
Nov 03, 2023	mitchell ronald paul	back to issuer	-	-	-79,332	-
Nov 03, 2023	schweitzer pamela	back to issuer	-	-	-79,220	-
Nov 03, 2023	beckwith samira	back to issuer	-	-	-88,299	-

Which funds bought or sold TRHC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-82.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-9,273,950	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-1,529,470	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-2,317,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-249,770	-	-%
Feb 15, 2024	Westchester Capital Management, LLC	sold off	-100	-2,260,360	-	-%
Feb 14, 2024	Mint Tower Capital Management B.V.	sold off	-100	-664,000	-	-%
Feb 14, 2024	Engineers Gate Manager LP	sold off	-100	-105,244	-	-%
Feb 14, 2024	Cubist Systematic Strategies, LLC	sold off	-100	-504,479	-	-%
Feb 14, 2024	Skandinaviska Enskilda Banken AB (publ)	sold off	-100	-1,245,000	-	-%

Are Funds Buying or Selling TRHC?

Are funds buying TRHC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TRHC

No. of Funds

Unveiling Tabula Rasa HealthCare Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 14, 2023	indaba capital management, l.p.	-	0	SC 13D/A
Aug 08, 2023	indaba capital management, l.p.	24.3%	6,521,578	SC 13D/A
Feb 09, 2023	vanguard group inc	4.40%	1,193,981	SC 13G/A
Sep 14, 2022	indaba capital management, l.p.	24.84%	6,521,578	SC 13D/A
Jul 28, 2022	indaba capital management, l.p.	25.23%	6,521,578	SC 13D/A
Jul 22, 2022	indaba capital management, l.p.	25.00%	6,462,316	SC 13D/A
Jul 08, 2022	blackrock inc.	2.2%	559,388	SC 13G/A
Jun 28, 2022	blackrock inc.	2.1%	531,827	SC 13D/A
Jun 21, 2022	blackrock inc.	5.8%	1,500,489	SC 13D/A
Jun 10, 2022	macquarie group ltd	0.0%	0	SC 13G/A

Peers (Alternatives to Tabula Rasa HealthCare Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	449.3B	371.6B	0.31%	-0.92%	20.08	1.21	14.64%	11.24%
CI	103.0B	195.3B	-0.92%	38.85%	19.17	0.53	8.17%	-20.79%
CVS	85.3B	357.8B	-14.21%	-7.01%	10.21	0.24	10.95%	93.52%
HCA	84.4B	65.0B	-2.46%	13.22%	16.11	1.3	7.86%	-7.11%
CNC	40.8B	154.0B	-1.12%	9.99%	15.09	0.26	6.54%	124.79%
DVA	11.6B	12.1B	-1.51%	52.05%	16.83	0.96	4.57%	23.40%
UHS	11.5B	14.3B	-6.67%	17.96%	16.03	0.81	6.59%	6.24%
MID-CAP
CHE	9.3B	2.3B	-4.23%	9.23%	34.28	4.13	6.06%	9.17%
ACHC	6.6B	2.9B	-6.62%	-3.50%	-303.23	2.24	12.20%	-107.93%
AMN	2.2B	3.8B	-8.18%	-34.26%	10.28	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-5.68%	1.59%	33.78	1.48	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-7.02%	-15.70%	24.79	1.46	11.31%	35.83%
BKD	1.3B	3.0B	4.49%	59.95%	-6.76	0.42	6.74%	20.73%
BEAT	54.0M	-	-6.82%	-	-3.69	-	-	-12.94%
AMS	19.1M	21.3M	14.29%	7.64%	35.87	0.9	8.00%	-62.25%

Tabula Rasa HealthCare Inc News

Latest updates

Tabula Rasa HealthCare Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	2.0%	90,036,000	88,277,000	82,708,000	77,101,000	72,597,000	67,110,000	68,897,000	67,910,000	64,297,000	58,778,000	1,222,000	70,506,000	76,834,000	72,827,000	73,223,000	74,270,000	76,255,000	60,959,000	57,310,000	54,418,000	48,598,000
Cost Of Revenue	0.0%	67,507,000	67,524,000	63,016,000	60,235,000	56,631,000	52,721,000	50,564,000	51,215,000	47,620,000	43,979,000	11,599,000	49,248,000	51,698,000	48,073,000	48,090,000	46,441,000	45,156,000	41,668,000	38,537,000	35,058,000	32,410,000
Operating Expenses	17.3%	31,561,000	26,909,000	37,023,000	40,515,000	26,054,000	32,296,000	29,117,000	26,139,000	28,482,000	25,507,000	-11,241,000	39,955,000	35,286,000	37,948,000	32,931,000	35,593,000	35,859,000	31,618,000	28,116,000	9,550,000	51,013,000
S&GA Expenses	11.4%	2,732,000	2,453,000	2,813,000	2,857,000	2,172,000	2,649,000	2,814,000	2,719,000	2,539,000	2,967,000	-7,452,000	5,030,000	5,027,000	5,540,000	6,668,000	6,884,000	6,871,000	4,850,000	2,682,000	2,669,000	2,314,000
R&D Expenses	38.9%	1,777,000	1,279,000	3,257,000	4,018,000	3,243,000	3,965,000	3,560,000	3,699,000	4,311,000	3,059,000	676,000	5,101,000	3,821,000	4,828,000	5,090,000	5,902,000	5,197,000	5,550,000	3,707,000	3,380,000	2,922,000
EBITDA Margin	14.7%	-0.13	-0.15	-0.21	-0.21	-0.16	-0.17	-0.16	-0.45	-0.44	-0.36	-0.30	-0.03	-	-	-	-	-	-	-	-	-
Interest Expenses	9.6%	-1,144,000	-1,265,000	-1,604,000	-2,717,000	-2,444,000	-2,269,000	-2,148,000	-2,230,000	-2,182,000	-2,547,000	-34,743,000	4,722,000	4,668,000	4,610,000	4,544,000	4,441,000	4,308,000	2,693,000	491,000	232,000	120,000
Income Taxes	26.7%	133,000	105,000	21,000	-7,000	159,000	216,000	106,000	82,000	81,000	121,000	296,000	-1,830,000	-508,000	-3,367,000	-5,518,000	-4,101,000	-2,539,000	-4,041,000	731,000	-838,000	-5,919,000
Earnings Before Taxes	-37.9%	-9,610,000	-6,969,000	-18,350,000	-25,887,000	-12,532,000	-20,176,000	-12,932,000	-11,674,000	-13,987,000	-13,255,000	-5,879,000	-23,419,000	-14,818,000	-17,804,000	-12,342,000	-12,205,000	-9,068,000	-15,020,000	-9,834,000	9,578,000	-34,945,000
EBT Margin	9.5%	-0.18	-0.20	-0.26	-0.25	-0.21	-0.22	-0.20	-0.23	-0.29	-0.28	-0.28	-0.23	-	-	-	-	-	-	-	-	-
Net Income	38.0%	-9,851,000	-15,898,000	-29,642,000	-40,065,000	-49,610,000	-28,193,000	-21,371,000	-17,111,000	-21,081,000	-19,492,000	-30,630,000	-21,589,000	-14,310,000	-14,437,000	-6,824,000	-8,104,000	-6,529,000	-10,979,000	-10,565,000	10,416,000	-29,026,000
Net Income Margin	33.0%	-0.28	-0.42	-0.49	-0.49	-0.42	-0.33	-0.30	-0.46	-0.48	-0.41	-0.37	-0.19	-	-	-	-	-	-	-	-	-
Free Cashflow	147.7%	4,516,000	-9,473,000	-3,660,000	363,000	24,321,000	-15,952,000	10,696,000	1,476,000	4,530,000	-4,600,000	-1,084,000	870,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	0.1%	356	356	384	404	484	507	499	501	504	503	514	458	483	488	492	499	508	510	271	235	200
Current Assets	2.6%	147	143	170	180	266	289	90.00	88.00	90.00	85.00	93.00	76.00	94.00	94.00	95.00	97.00	103	101	63.00	53.00	39.00
Cash Equivalents	-6.5%	63.00	67.00	70.00	81.00	27.00	14.00	9.00	11.00	11.00	17.00	23.00	29.00	39.00	38.00	42.00	47.00	52.00	50.00	25.00	13.00	6.00
Inventory	17.2%	9.00	7.00	7.00	6.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00
Goodwill	0%	115	115	115	115	115	115	115	171	171	171	171	20.00	151	151	151	151	151	166	12.00	91.00	78.00
Liabilities	1.8%	434	426	441	435	491	471	444	434	428	419	346	294	309	308	307	314	324	327	132	137	120
Current Liabilities	8.5%	94.00	86.00	102	98.00	154	76.00	74.00	65.00	66.00	62.00	72.00	34.00	39.00	40.00	40.00	44.00	52.00	56.00	76.00	107	108
Long Term Debt	-	89.00	-	89.00	-	-	-	-	-	-	-	-	236	233	229	226	-	-	217	0.00	-	-
LT Debt, Non Current	-	89.00	-	89.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-	-	-	-	-	-	36.00	56.00	67.00	76.00	84.00	169	165	173	179	186	185	184	183	139	98.00	80.00
Retained Earnings	-2.3%	-433	-423	-407	-378	-338	-288	-260	-238	-221	-200	-179	-149	-127	-113	-98.93	-92.11	-84.01	-77.48	-66.50	-55.93	-66.35
Additional Paid-In Capital	0.7%	360	357	354	350	336	329	320	311	302	289	352	318	305	297	288	281	272	264	209	157	150
Shares Outstanding	0.7%	27.00	27.00	27.00	27.00	24.00	24.00	26.00	23.00	23.00	23.00	22.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	49.00	-	-	-	648	-	-	-	907	-	-	-	818	-	-	-	1,021

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	158.3%	5,107	-8,754	-2,396	913	24,575	-15,735	12,435	2,117	4,978	-4,078	-530	1,960	4,185	-797	996	9,054	10,781	-26,646	6,587	5,482	3,552
Share Based Compensation	-	-	-	-	-	-	-	9,492	8,011	12,349	8,602	10,147	8,098	7,173	7,137	6,295	7,225	6,906	6,852	3,240	2,996	2,180
Cashflow From Investing	-3040.6%	-5,293	180	-2,378	112,021	-9,375	-8,966	-10,934	-9,279	-8,596	-6,385	-12,463	-5,926	-5,354	-4,991	-6,474	-6,563	-6,513	-161,375	-14,750	-17,352	-9,524
Cashflow From Financing	91.8%	-33.00	-403	-1,060	-58,308	-	27,410	-1,156	5,601	347	2,124	9,231	-5,624	1,156	1,104	990	-8,124	-1,445	216,871	19,245	18,544	8,993
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TRHC Income Statement

2023-06-30

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Total revenue	$ 90,036	$ 72,597	$ 178,313	$ 139,707
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	67,507	56,631	135,031	109,352
Operating expenses:
Research and development	1,777	3,243	3,056	7,208
Sales and marketing	2,732	2,172	5,185	4,821
General and administrative	17,599	15,150	34,176	31,028
Change in fair value of contingent consideration receivable	3,350		3,750
Long-lived asset impairment charge				4,062
Depreciation and amortization	6,103	5,489	12,303	11,231
Total operating expenses	31,561	26,054	58,470	58,350
Loss from operations	(9,032)	(10,088)	(15,188)	(27,995)
Other income (expense):
Interest expense, net	(1,144)	(2,444)	(2,409)	(4,713)
Other income	566		1,018
Total other expense, net	(578)	(2,444)	(1,391)	(4,713)
Loss from continuing operations before income taxes	(9,610)	(12,532)	(16,579)	(32,708)
Income tax expense	133	159	238	375
Net loss from continuing operations	(9,743)	(12,691)	(16,817)	(33,083)
Net loss from discontinued operations, net of tax	(108)	(36,919)	(8,932)	(44,720)
Net loss	$ (9,851)	$ (49,610)	$ (25,749)	$ (77,803)
Net loss per share:
Net loss per share from continuing operations, basic (in dollars per share)	$ (0.38)	$ (0.53)	$ (0.66)	$ (1.38)
Net loss per share from discontinued operations, basic (in dollars per share)		(1.54)	(0.35)	(1.87)
Total net loss per share, basic (in dollars per share)	(0.38)	(2.07)	(1.01)	(3.25)
Net loss per share from continuing operations, diluted (in dollars per share)	(0.38)	(0.53)	(0.66)	(1.38)
Net loss per share from discontinued operations, diluted (in dollars per share)		(1.54)	(0.35)	(1.87)
Total net loss per share, diluted (in dollars per share)	$ (0.38)	$ (2.07)	$ (1.01)	$ (3.25)
Weighted average common shares outstanding:
Weighted average common shares outstanding, basic (in shares)	25,422,032	23,959,726	25,333,137	23,913,050
Weighted average common shares outstanding, diluted (in shares)	25,422,032	23,959,726	25,333,137	23,913,050
Medication
Revenue:
Total revenue	$ 69,626	$ 55,892	$ 138,376	$ 106,865
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	53,554	43,384	106,636	82,936
Technology-enabled solutions
Revenue:
Total revenue	20,410	16,705	39,937	32,842
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	$ 13,953	$ 13,247	$ 28,395	$ 26,416

TRHC Balance Sheet

2023-06-30

UNAUDITED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 62,811	$ 70,017
Restricted cash	10,400	12,372
Accounts receivable, net of allowance of $935 and $368, respectively	18,610	19,252
Inventories	8,659	6,566
Prepaid expenses	3,581	4,664
Client claims receivable	16,415	16,377
Divestiture-related note receivable	3,527
Other current assets	22,678	18,187
Current assets of discontinued operations		22,825
Total current assets	146,681	170,260
Property and equipment, net	9,369	9,158
Operating lease right-of-use assets	10,149	10,483
Software development costs, net	33,077	32,592
Goodwill	115,323	115,323
Intangible assets, net	35,129	38,326
Contingent consideration receivable		3,350
Other assets	6,209	4,657
Total assets	355,937	384,149
Current liabilities:
Current operating lease liabilities	2,982	2,708
Accounts payable	20,623	19,459
Client claims payable	10,981	10,781
Accrued expenses and other liabilities	59,105	55,745
Current liabilities of discontinued operations		13,389
Total current liabilities	93,691	102,082
Noncurrent operating lease liabilities	12,102	12,786
Deferred income tax liability, net	1,507	1,380
Other long-term liabilities	5,404	4,298
Total liabilities	434,016	441,180
Commitments and contingencies (Note 16)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value; 100,000,000 shares authorized, 28,360,785 and 28,031,616 shares issued and 27,058,420 and 27,129,096 shares outstanding at June 30, 2023 and December 31, 2022, respectively	3	3
Treasury stock, at cost; 1,302,365 and 902,520 shares at June 30, 2023 and December 31, 2022, respectively	(4,049)	(3,391)
Additional paid-in capital	359,573	354,214
Accumulated deficit	(433,606)	(407,857)
Total stockholders' deficit	(78,079)	(57,031)
Total liabilities and stockholders' deficit	355,937	384,149
Nonrelated Party
Current liabilities:
Long-term debt, net of discount	232,603	232,112
Related Party
Current liabilities:
Long-term debt, net of discount	$ 88,709	$ 88,522

About Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise Risk Score, a medication risk stratification technology for identification of patients in need of clinical intervention. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third-party administrator services. As of December 31, 2022, it served approximately 150 healthcare organizations. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.

CEO	Mr. Brian W. Adams
WEBSITE	tabularasahealthcare.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1027

Tabula Rasa HealthCare Inc Frequently Asked Questions

What is the ticker symbol for Tabula Rasa HealthCare Inc? What does TRHC stand for in stocks?

TRHC is the stock ticker symbol of Tabula Rasa HealthCare Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tabula Rasa HealthCare Inc (TRHC)?

As of Tue Nov 07 2023, market cap of Tabula Rasa HealthCare Inc is 284.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRHC stock?

You can check TRHC's fair value in chart for subscribers.

What is the fair value of TRHC stock?

You can check TRHC's fair value in chart for subscribers. The fair value of Tabula Rasa HealthCare Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tabula Rasa HealthCare Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TRHC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tabula Rasa HealthCare Inc a good stock to buy?

The fair value guage provides a quick view whether TRHC is over valued or under valued. Whether Tabula Rasa HealthCare Inc is cheap or expensive depends on the assumptions which impact Tabula Rasa HealthCare Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRHC.

What is Tabula Rasa HealthCare Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 07 2023, TRHC's PE ratio (Price to Earnings) is -2.98 and Price to Sales (PS) ratio is 0.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRHC PE ratio will change depending on the future growth rate expectations of investors.